ModifiedHealth NetPolicy CP.PHAR.112

Ponatinib (Iclusig) Coverage Criteria

Defines medical necessity criteria, prior authorization requirements, and coverage limits for ponatinib (Iclusig) for adult and select pediatric patients with Philadelphia chromosome–positive leukemias and certain off-label malignancies for Health Net/Centene-affiliated plans.

Policy Summary

PayerHealth Net

PolicyPonatinib (Iclusig) Coverage Criteria

Policy CodePolicy CP.PHAR.112

Change TypeMultiple material revisions (approval durations, dosing, step therapy/redirects, off-label additions)

Effective DateJun 1, 2013

Next Review Date

Key ActionSubmit prior authorization with clinical documentation demonstrating diagnosis, prior TKI history or mutation status, and intended dosing to meet approval criteria.

SourceLink

POLICY UPDATE CHANGES

Modified commercial and Medicaid/HIM approval durations and consolidated approval durations for initial and continuation therapy.

Clarified CML criteria: 2-TKI requirement applies to chronic phase CML; accelerated/blast phase may qualify if no other TKI is indicated.

Added off-label criteria set for lymphoid, myeloid or mixed lineage neoplasms with redirection to imatinib for ABL1 rearrangement-positive disease unless state regulations prohibit step therapy.

Added indications and dosing for newly diagnosed Ph+ ALL including a new starting dose per updated prescribing information.

Added off-label GIST criteria per NCCN Compendium and quantity limit of one tablet per day.

12 monthstypical approval duration

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Ponatinib (Iclusig)

Initial Therapy — I. Initial Approval Criteria

Covered when ALL of the following are met for each indication group:

Chronic Myeloid Leukemia (CML) initial: 1. Diagnosis of Ph+ (BCR-ABL1-positive) CML; 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. Member meets one of: (a) chronic phase CML with resistance, toxicity, or intolerance to ≥2 prior TKIs (e.g., imatinib, bosutinib, dasatinib, nilotinib); (b) accelerated or blast phase CML for members for whom no other TKI therapy is indicated; (c) BCR-ABL T315I mutation; 5. For brand Iclusig requests, member must use generic ponatinib if available unless contraindicated or clinically significant adverse effects; 6. Dose does not exceed 45 mg per day (one tablet per day) OR dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); 7. Prescribed regimen must be FDA-approved or recommended by NCCN.

Acute Lymphoblastic Leukemia (ALL) initial: 1. Diagnosis of Ph+ (BCR-ABL1-positive) ALL; 2. Prescribed by or in consultation with an oncologist or hematologist; 3. One of the following: (a) Age ≤ 18 years and request is for (i) relapsed or refractory BCR::ABL1-positive B-cell ALL (off-label) or (ii) T-cell ALL with ABL-class translocation (off-label); OR (b) Age ≥ 18 years and member meets one of: (i) BCR-ABL T315I mutation; (ii) no other TKI therapy is indicated; (iii) newly diagnosed ALL for use in combination with chemotherapy or corticosteroid; 4. For brand Iclusig requests, member must use generic ponatinib if available unless contraindicated or clinically significant adverse effects; 5. Dose does not exceed one of the following: (a) newly diagnosed ALL as combination therapy: 30 mg/day; (b) all other requests: 45 mg/day; OR one tablet per day; OR dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); 6. Prescribed regimen must be FDA-approved or recommended by NCCN.

Myeloid/Lymphoid Neoplasms with FGFR1/ABL1 rearrangement (off-label) initial: 1. Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia and FGFR1 or ABL1 rearrangement in blast or chronic phase; 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. If ABL1 rearrangement positive, one of: (a) contraindication, intolerance, or disease progression on imatinib; OR (b) request is for treatment in a State with regulations against step therapy (see Appendix E); 5. For brand Iclusig requests, member must use generic ponatinib if available unless contraindicated or clinically significant adverse effects; 6. Dose is within FDA maximum limit for any FDA-approved indication OR is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); 7. Prescribed regimen must be FDA-approved or recommended by NCCN.

Gastrointestinal Stromal Tumors (GIST) off-label initial: 1. Diagnosis of gastrointestinal stromal tumor (GIST); 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Failure of imatinib, ripretinib (Qinlock), sunitinib, or regorafenib unless contraindicated or intolerant; 5. Prescribed as a single agent; 6. For brand Iclusig requests, member must use generic ponatinib if available unless contraindicated or clinically significant adverse effects; 7. Dose is within FDA maximum limit for any FDA-approved indication OR is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); 8. Prescribed regimen must be FDA-approved or recommended by NCCN.

Continuation Therapy

Covered when ALL of the following are met:

Continuation of Therapy: 1. Member is currently receiving medication via Centene benefit OR documentation supports current receipt of Iclusig for a covered indication and has received the medication for at least 30 days; 2. Member is responding positively to therapy; 3. For brand Iclusig requests, member must use generic ponatinib if available unless contraindicated or clinically significant adverse effects; 4. If request is for a dose increase, new dose must not exceed: (a) 30 mg/day for newly diagnosed ALL in combination therapy; or (b) 45 mg/day for all other requests; OR be one tablet per day; OR be supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); 5. Prescribed regimen must be FDA-approved or recommended by NCCN.

Other/Off-Policy Uses

Other uses (off-label/compendium) — follow the referenced policies when criteria below apply:

Other/Off-Policy Uses: 1. If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy, refer to the relevant formulary or non-formulary policy for the line of business (commercial, marketplace/ICHRA, Medicaid) as listed in the policy; OR 2. If the requested use is not listed in Section III (Diagnoses/Indications not authorized) and criterion 1 does not apply, refer to the off-label use policy for the relevant line of business (policies CP.CPA.09, HIM.PA.154, CP.PMN.53 as cited).

Indication-specific coverage criteria

Covered when ALL of the following are met for each indication as specified:

Accelerated or blast phase CML and Ph+ ALL (monotherapy or T315I-positive): Starting dose 45 mg PO QD; consider dose reduction in accelerated phase CML patients who have achieved a major cytogenetic response; maximum dose = 45 mg/day.

Chronic phase CML: Starting dose 45 mg PO QD with reduction to 15 mg PO QD upon achievement of ≤ 1% BCR-ABL1; patients with loss of response may re-escalate to a previously tolerated dose of 30 mg or 45 mg PO QD; maximum dose = 45 mg/day.

Newly diagnosed Ph+ ALL: Starting dose 30 mg PO QD in combination with chemotherapy with reduction to 15 mg PO QD upon MRD-negative (≤ 0.01% BCR::ABL1/ABL1) complete remission at end of induction; maximum dose = 30 mg/day.

ALL additional conditions: Policy revised: for ALL, either presence of BCR-ABL T315I mutation OR no other TKI therapy is indicated; pediatric relapsed/refractory options exist per updated guidance and NCCN compendium additions.

Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider supplies sufficient supporting documentation per the applicable off‑label use policies. For commercial members follow CP.CPA.09, for health insurance marketplace/ICHRA follow HIM.PA.154, and for Medicaid follow CP.PMN.53, or provide an evidence of coverage document that supports the requested use.

Although no absolute contraindications are reported in the appendices, ponatinib carries multiple boxed warnings that require careful consideration prior to authorization: arterial occlusion, venous thromboembolism (VTE), heart failure, and hepatotoxicity. These safety risks should be reviewed and documented in the clinical record when assessing medical necessity.

Per the FDA‑approved labeling, ponatinib (Iclusig) is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia (CML). Requests for ponatinib in this setting should be denied unless an alternative, documented indication consistent with this policy is provided.

Requests for ponatinib that do not meet the specific criteria sets in this policy (for example, failure to document required prior TKI trials for chronic phase CML, absence of a qualifying BCR‑ABL mutation or justification that no other TKI is indicated for ALL, or exceeding quantity/dosing limits) are considered not medically necessary and will not be authorized.

Line of Therapy Requirements

second-line_or_later

second-line_or_later: Chronic phase: require resistance/intolerance to ≥2 prior TKIs before ponatinib; accelerated/blast phase allowed when no other TKI is indicated; T315I mutation may qualify regardless of prior lines.

first-line | second-line

first-line | second-line: Newly diagnosed Ph+ ALL: ponatinib in combination with chemotherapy (accelerated approval) as initial therapy; other ALL uses may be for relapsed/refractory disease, T315I mutation, or when no other TKI is indicated.

second-line

second-line: Per policy, 2 prior TKIs are required for chronic phase CML (clarified to apply to chronic phase); accelerated/blast phase permitted if no other TKI is indicated.

Biomarker and Mutation Requirements

inv-24: BCR-ABL T315I — key value (mutation requirement)

Required biomarkerPresence of BCR-ABL T315I mutation (T315I-positive CML or Ph+ ALL)

Indications where relevantChronic, accelerated, or blast phase CML and Ph+ ALL when T315I-positive

Line of therapy implicationT315I mutation may qualify regardless of prior TKI lines (i.e., may be used when mutation present even if prior TKIs not met)

Dose guidanceFollow indication-specific dosing: e.g., monotherapy starting 45 mg PO QD for accelerated/blast phase CML and T315I-positive Ph+ ALL; maximum 45 mg/day

inv-25: BCR-ABL (T315I) — presence of T315I mutation qualifies for use when specified

Qualification statementPresence of BCR-ABL (T315I) mutation qualifies the member for ponatinib use when specified in the criteria (e.g., T315I-positive CML or Ph+ ALL)

Dosing, Regimens, and Quantity Limits

Regimen	Indication / Notes	Coverage Status
Ponatinib 30 mg PO once daily in combination with chemotherapy
Newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). Accelerated approval; continued approval contingent on confirmatory trials. Combination chemotherapy examples in policy: cyclophosphamide, vincristine, doxorubicin, daunorubicin, cytarabine, methotrexate, or corticosteroid per NCCN/prescribing information.
Dose reductions: reduce to 15 mg PO QD upon achievement of MRD‑negative (≤0.01% BCR::ABL1/ABL1) complete remission at end of induction as described in dosing guidance.

Regimen	Indication / Notes	Coverage Status
Ponatinib up to 45 mg PO once daily (one tablet daily)
Applies to most indications (CML phases, Ph+ leukemias, and other covered uses). Policy limits dose to ≤45 mg/day except when higher dose is supported by practice guidelines or peer‑reviewed literature with submitted evidence. For brand Iclusig requests, generic ponatinib must be used if available unless contraindicated.
Quantity limit: one tablet per day (policy applies a single‑tablet daily maximum); dose adjustments permitted per guidelines or literature with documentation.

Regimen	Indication / Notes	Coverage Status
Ponatinib monotherapy starting 45 mg PO QD with dose adjustments per response
Accelerated‑phase or blast‑phase chronic myeloid leukemia (CML) and Ph+ ALL, including T315I‑positive disease. Consider dose reduction in accelerated phase CML after achievement of a major cytogenetic response; maximum dose 45 mg/day.
Patients may have dose reduced per clinical response and safety; continuation requires documented benefit and adherence to dose limits or supporting literature for deviations.

Regimen	Indication / Notes	Coverage Status
Ponatinib starting 45 mg PO QD with reduction to 15 mg PO QD upon achievement of ≤1% BCR‑ABL1; re‑escalation permitted for loss of response
Chronic phase CML. Starting dose 45 mg daily; reduce to 15 mg daily when patient achieves ≤1% BCR‑ABL1. If loss of response occurs, re‑escalation to a previously tolerated dose (30 mg or 45 mg PO QD) is allowed. Maximum 45 mg/day.
Policy requires documentation of prior TKI exposures or other qualifying criteria for chronic phase CML per initial approval criteria; brand requests should use generic when available.

Regimen	Indication / Notes	Coverage Status
Ponatinib 30 mg PO QD with reduction to 15 mg PO QD upon MRD‑negative complete remission; combination therapy per prescribing information
Newly diagnosed Ph+ ALL in combination with chemotherapy (including option for corticosteroid per NCCN). Starting dose 30 mg daily; reduce to 15 mg daily upon MRD‑negative (≤0.01% BCR::ABL1/ABL1) complete remission at end of induction. Maximum dose for this indication is 30 mg/day and combination duration guidance per PI (policy notes recommended cycles in appendix).
Coverage is under accelerated approval; continued approval contingent on confirmatory trials. For ALL, age and other eligibility criteria apply per policy (including adult age requirements and pediatric options where specified).

Prior Authorization, Documentation, and Step Therapy

Prior Authorization

Prior Authorization Required

Prior authorization required. Provider must obtain prior authorization before dispensing Iclusig (ponatinib). Requests that do not meet the clinical criteria, step therapy requirements, or lack required documentation will be denied or returned for additional information.

Prior authorization required for all indications in this policy.
Approval durations: initial and continuation approval periods follow payer-specific guidance; see policy header and change log for consolidated approval durations.

Documentation Required

Documentation Required to Avoid Denial

Provider must submit supporting clinical documentation to avoid denial. Acceptable documentation includes office chart notes, diagnostic test results, BCR‑ABL mutation testing reports, prior treatment history (including dates, agents, and responses), and rationale for using brand product instead of generic (if applicable). Failure to submit required documentation may result in denial or a request for additional information.

Background and Product Information

Ponatinib (Iclusig) is an oral multi‑targeted tyrosine kinase inhibitor indicated for select adult patients with Philadelphia chromosome–positive (BCR‑ABL1–positive) leukemias. FDA‑approved indications include: treatment of chronic phase CML with resistance or intolerance to at least two prior kinase inhibitors; accelerated‑ or blast‑phase CML or Ph+ acute lymphoblastic leukemia (ALL) when no other TKI is indicated; T315I‑positive CML or T315I‑positive Ph+ ALL; and newly diagnosed Ph+ ALL in combination with chemotherapy under accelerated approval. The product carries boxed warnings for serious vascular and hepatic toxicities and is not indicated for newly diagnosed chronic phase CML. Dosing and duration vary by indication and are limited by the maximum labeled dose (commonly up to 45 mg/day for most indications, with lower approved starting doses for newly diagnosed Ph+ ALL when used in combination therapy).

Key Definitions

inv-18: Ph+ — Philadelphia chromosome–positive (BCR-ABL1–positive) disease definition

DefinitionPhiladelphia chromosome–positive disease defined as BCR-ABL1–positive (Ph+)

Applies toChronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL)

AbbreviationPh+ denotes Philadelphia chromosome–positive (BCR-ABL1–positive)

inv-19: Philadelphia chromosome-positive — shorthand 'Ph+'

ShorthandPh+ stands for Philadelphia chromosome–positive

Clinical relevanceUsed to describe BCR-ABL1–positive leukemias such as CML and Ph+ ALL

Policy Revision History

2026-03-26approval_duration_revisionLatest

Medicaid/HIM initial approval duration revised from 6 months to 12 months (2Q2026 annual review).

2025-01-16clinical_update

Added option for combination use with corticosteroid for newly diagnosed ALL and pediatric use options for relapsed/refractory BCR::ABL1-positive ALL per NCCN Compendium (2Q2025 annual review).

2022-09-30

Policy Summary

PayerHealth Net

PolicyPonatinib (Iclusig) Coverage Criteria

Policy CodePolicy CP.PHAR.112

Change TypeMultiple material revisions (approval durations, dosing, step therapy/redirects, off-label additions)

Effective DateJun 1, 2013

Next Review Date

Key ActionSubmit prior authorization with clinical documentation demonstrating diagnosis, prior TKI history or mutation status, and intended dosing to meet approval criteria.

SourceLink

On This Page

Step Therapy

Step Therapy / Redirection

Step therapy / redirection applies for ABL1‑rearrangement positive myeloid/lymphoid neoplasms and certain CML indications: prescribers must document intolerance, contraindication, or disease progression on imatinib before approval of Iclusig, unless a state regulation prohibits step therapy in the oncology setting or other policy exceptions apply. For chronic phase CML, prior therapy with two or more TKIs is required unless accelerated/blast phase or T315I mutation criteria apply. Requests should document why imatinib or other generic oral oncology agents are not appropriate when redirection is available.

Imatinib redirection required for ABL1 rearrangement positive neoplasms unless member has contraindication, intolerance, or disease progression on imatinib.
For chronic phase CML, member must have resistance/toxicity/intolerance to two or more TKIs (e.g., imatinib, bosutinib, dasatinib, nilotinib) unless alternative criteria in policy apply.
State exceptions: do not apply step therapy/redirection in states listed in Appendix E where step therapy is prohibited for specified oncology settings (see Appendix E for state-specific details).
Prescriber must document clinical rationale if requesting bypass of step therapy (e.g., mutation status T315I, rapid disease progression, or regulatory/protocol exceptions).